Bayer, Clinches

Bayer Clinches First-in-Class Stroke Approval, Lifts Outlook — Yet Jefferies Stays on the Fence

Published on 11/16/2026 at 13:31 | Editorial boerse-global.de
FDA approves Bayer's Asundexian as Sunharbo for stroke risk; Q3 revenue hits EUR 10.053 billion and 2026 guidance rises despite a EUR 672 million loss.
Bayer, Clinches, First-in-Class, Stroke, Approval, Lifts, Outlook, Yet, Jefferies, Stays Illustration mit AI erstellt.

Bayer's autumn has been busy on regulatory, legal and corporate fronts, and the market has had plenty to weigh up. The most eye-catching item came in the past week: the US Food and Drug Administration granted approval to the company's active ingredient Asundexian, which will be marketed under the brand name Sunharbo. According to company statements dated 10 November, the drug is intended to lower the risk of further strokes in certain adult patients, and it is cleared for use alongside an antiplatelet therapy.

The label is tightly drawn. Sunharbo may be prescribed for adults following a non-cardioembolic ischemic stroke or a high-risk TIA — nothing broader. Bayer is keen to stress the milestone: Sunharbo is the first approved factor XIa inhibitor of its kind.

Guidance Raised Despite a Quarterly Loss

The approval lands alongside improved operating figures. In its third-quarter 2026 report published on 3 November, Bayer posted group revenue of EUR 10.053 billion. EBITDA before special items came in at EUR 1.615 billion, while the bottom line showed a negative group result of EUR 672 million. The headline loss and the positive adjusted operating profit reflect different earnings measures for the same quarter, and the company paired the release with an upgraded forecast for the full year 2026.

Should investors sell immediately? Or is it worth buying Bayer?

Investors responded with restraint rather than euphoria. The stock closed at EUR 56.66 on Friday, edging up 0.2% on the day, after Bayer had announced the US approval earlier in the week.

Two Courts, Two Wins

Legal developments also broke Bayer's way. A Missouri jury rejected claims brought by three plaintiffs against Bayer subsidiary Monsanto on 9 November, according to Reuters. That verdict settles only the individual case at hand and carries no bearing on the pending global settlement.

On the European side, the renewed EU approval of glyphosate survived a challenge. The General Court of the European Union dismissed a suit filed by Antidote Europe on 4 November. Bayer had joined the proceedings in support of the European Commission.

The Street Remains Divided

Analysts are not reading from the same page. Deutsche Bank, as reported on 10 November, raised its price target on Bayer from EUR 60 to EUR 65 while keeping its "Buy" rating — a clear vote of confidence in the equity. Jefferies took the opposite stance that same day, reaffirming its "Hold" recommendation and leaving its EUR 48.50 target untouched. The split verdict arrived just as news of the Sunharbo approval was circulating, leaving investors to decide which side of the argument carries more weight.

Ad

Bayer Stock: New Analysis - 16 November

Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Bayer analysis...

Disclaimer...
en | DE000BAY0017 | BAYER | boerse | 70520801 |